Journal
HORMONE RESEARCH IN PAEDIATRICS
Volume 95, Issue 2, Pages 177-192Publisher
KARGER
DOI: 10.1159/000518432
Keywords
Pharmacological treatment; Obesity; Monogenic obesity; MC4R
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) through CRC 1423 [421152132, KU 2673/6-1]
Ask authors/readers for more resources
This review discusses pharmacological therapeutic options for obese children and adolescents and compares them with conservative treatment approaches. Understanding underlying molecular mechanisms can help identify effective antiobesity drugs and modify current treatment strategies to assist obese children and adolescents in losing weight.
Background: The increasing number of obese children and adolescence is a major problem in health-care systems. Currently, the gold standard for the treatment of these patients with obesity is a multicomponent lifestyle intervention. Unfortunately, this strategy is not leading to a substantial and long-lasting weight loss in the majority of patients. This is the reason why there is an urgent need to establish new treatment strategies for children and adolescents with obesity to reduce the risk for the development of any comorbidities like cardiovascular diseases or diabetes mellitus type 2. Summary: In this review, we outline available pharmacological therapeutic options for children and compare the available study data with the outcome of conservative treatment approaches. Key Messages: We discussed, in detail, how knowledge about underlying molecular mechanisms might support the identification of effective antiobesity drugs in the future and in which way this might modulate current treatment strategies to support children and adolescence with obesity to lose body weight. (C) 2021 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available